Pharma

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Most Viewed Abstracts



Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

ImmunoGen, Inc. , a biopharmaceutical company that develops targeted anticancer therapeutics, announced that it has priced a public offering of 5,000,000 shares of its common stock at a price of $7.00 per share. Net proceeds, after underwriting discounts and commissions and expenses, will be approximately $33 million. ImmunoGen has granted the underwriters a thirty day option to purchase up to an additional 750,000 shares to cover over-allotments, if any.

Today in Research & Development...keeping you current

New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists
Amgen, 12/04/09

Bayer Team wins the “Deutscher Zukunftspreis” awarded by the German President
BayNews International, 12/03/09

GSK Update: GSKs Arepanrix H1N1 pandemic vaccine prequalified by the World Health Organization
GlaxoSmithKline, 12/02/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address